RU2584348C2 - Композиционная коллагеновая губка и способ ее изготовления - Google Patents
Композиционная коллагеновая губка и способ ее изготовления Download PDFInfo
- Publication number
- RU2584348C2 RU2584348C2 RU2014103549/15A RU2014103549A RU2584348C2 RU 2584348 C2 RU2584348 C2 RU 2584348C2 RU 2014103549/15 A RU2014103549/15 A RU 2014103549/15A RU 2014103549 A RU2014103549 A RU 2014103549A RU 2584348 C2 RU2584348 C2 RU 2584348C2
- Authority
- RU
- Russia
- Prior art keywords
- collagen
- procedure
- collagen sponge
- protective agent
- sponge
- Prior art date
Links
- 239000000515 collagen sponge Substances 0.000 title claims abstract description 60
- 239000002131 composite material Substances 0.000 title claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 title claims description 18
- 108010035532 Collagen Proteins 0.000 claims abstract description 76
- 102000008186 Collagen Human genes 0.000 claims abstract description 76
- 229920001436 collagen Polymers 0.000 claims abstract description 76
- 230000002779 inactivation Effects 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 52
- 230000003612 virological effect Effects 0.000 claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000003223 protective agent Substances 0.000 claims abstract description 32
- 150000001413 amino acids Chemical class 0.000 claims abstract description 22
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 102000009027 Albumins Human genes 0.000 claims abstract description 9
- 108010088751 Albumins Proteins 0.000 claims abstract description 9
- 230000010261 cell growth Effects 0.000 claims abstract description 9
- 239000003599 detergent Substances 0.000 claims abstract description 9
- 239000003102 growth factor Substances 0.000 claims abstract description 9
- 239000003960 organic solvent Substances 0.000 claims abstract description 8
- 230000000740 bleeding effect Effects 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 46
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 29
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 26
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 26
- 229920000053 polysorbate 80 Polymers 0.000 claims description 26
- 229940068968 polysorbate 80 Drugs 0.000 claims description 26
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- 229940024606 amino acid Drugs 0.000 claims description 21
- 235000001014 amino acid Nutrition 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 238000010521 absorption reaction Methods 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 8
- 239000001632 sodium acetate Substances 0.000 claims description 8
- 235000017281 sodium acetate Nutrition 0.000 claims description 8
- 239000007858 starting material Substances 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 102000057297 Pepsin A Human genes 0.000 claims description 5
- 108090000284 Pepsin A Proteins 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 229940111202 pepsin Drugs 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 238000005277 cation exchange chromatography Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000005185 salting out Methods 0.000 claims description 4
- 229940093635 tributyl phosphate Drugs 0.000 claims description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003729 cation exchange resin Substances 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 238000010612 desalination reaction Methods 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- 238000005238 degreasing Methods 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 238000004237 preparative chromatography Methods 0.000 claims description 2
- 238000012414 sterilization procedure Methods 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 238000001952 enzyme assay Methods 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 4
- 230000035409 positive regulation of cell proliferation Effects 0.000 abstract 1
- 230000017363 positive regulation of growth Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 17
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 16
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000000463 material Substances 0.000 description 14
- 206010052428 Wound Diseases 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 229940126864 fibroblast growth factor Drugs 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 239000013068 control sample Substances 0.000 description 7
- 230000000975 bioactive effect Effects 0.000 description 6
- 238000011097 chromatography purification Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 2
- 206010052369 Encephalitis lethargica Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000724675 Hepatitis E virus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 239000003181 biological factor Substances 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 201000002498 viral encephalitis Diseases 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 108010077465 Tropocollagen Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- RXNBDWQDJKUHNH-UHFFFAOYSA-L azane;cobalt(2+);dithiocyanate Chemical compound N.[Co+2].[S-]C#N.[S-]C#N RXNBDWQDJKUHNH-UHFFFAOYSA-L 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/102—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
- A61L2300/214—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102127130A CN102357259A (zh) | 2011-07-28 | 2011-07-28 | 一种生物蛋白海绵及其制备方法 |
| CN201110212713.0 | 2011-07-28 | ||
| PCT/CN2012/076577 WO2013013537A1 (zh) | 2011-07-28 | 2012-06-07 | 一种复合胶原蛋白海绵及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014103549A RU2014103549A (ru) | 2015-09-10 |
| RU2584348C2 true RU2584348C2 (ru) | 2016-05-20 |
Family
ID=45582674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014103549/15A RU2584348C2 (ru) | 2011-07-28 | 2012-06-07 | Композиционная коллагеновая губка и способ ее изготовления |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9439999B2 (enExample) |
| EP (1) | EP2737910B1 (enExample) |
| JP (1) | JP5887407B2 (enExample) |
| KR (2) | KR20140034938A (enExample) |
| CN (1) | CN102357259A (enExample) |
| RU (1) | RU2584348C2 (enExample) |
| WO (1) | WO2013013537A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018074951A1 (ru) * | 2016-10-21 | 2018-04-26 | Балабаньян, Вадим Юрьевич | Антибактериальная белковая губка для химиотерапии инфицированных ран и способ ее получения |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102357259A (zh) | 2011-07-28 | 2012-02-22 | 王珊珊 | 一种生物蛋白海绵及其制备方法 |
| KR101531479B1 (ko) * | 2014-11-21 | 2015-06-26 | 세원셀론텍(주) | 의료용 재료로 사용하기 위한 고농도 콜라겐 제조방법 |
| CN105126084A (zh) * | 2015-07-29 | 2015-12-09 | 广州赛莱拉生物基因工程有限公司 | 一种胶原蛋白组合物及其制备方法 |
| CN107349463A (zh) * | 2017-06-16 | 2017-11-17 | 卓阮医疗科技（苏州）有限公司 | 一种生物源性止血微粒及其制备方法 |
| WO2019074886A1 (en) | 2017-10-09 | 2019-04-18 | Terumo Bct Biotechnologies, Llc | LYOPHILIZATION CONTAINER AND METHOD OF USE |
| US11884953B2 (en) | 2017-10-11 | 2024-01-30 | Shuang Liu | Method for preparing protein peptide based on connective tissue and prepared protein peptide and use thereof |
| CN107827974B (zh) * | 2017-11-10 | 2021-01-01 | 中国科学院过程工程研究所 | 一种人纤维蛋白原的制备方法 |
| CN111084788A (zh) * | 2018-10-22 | 2020-05-01 | 上海蓝盎电子科技发展有限公司 | 人工细胞间质 |
| CN109985271B (zh) * | 2019-02-26 | 2021-10-22 | 百澳瑞派（天津）生物科技有限公司 | 一种用于难愈合创面修复的复合胶原敷料及其制备方法 |
| US11609042B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| CN114099761B (zh) * | 2020-08-27 | 2022-06-21 | 厦门大学 | 一种浴海绵止血材料及其制备方法和应用 |
| CN112999096A (zh) * | 2021-03-31 | 2021-06-22 | 广州源肽生物科技有限公司 | 一种含活性多肽美容制品冻干海绵及其制备方法 |
| CN114225020B (zh) * | 2021-12-31 | 2023-05-02 | 暨南大学 | 一种ova淀粉样蛋白原纤维及其制备方法与应用 |
| CN114632183B (zh) * | 2022-03-30 | 2023-02-03 | 温州医科大学 | 一种创伤蛋白海绵及其制备方法和在制备皮肤修复中减少瘢痕形成的药物中的应用 |
| CN116139337B (zh) * | 2022-12-30 | 2026-04-07 | 江苏江山聚源生物技术有限公司 | 重组人源胶原蛋白交联海绵及其制备方法 |
| CN118384313B (zh) * | 2024-04-23 | 2024-11-08 | 暨南大学 | 胶原蛋白-可得然胶复合止血凝胶海绵及其制备和应用 |
| CN121248762A (zh) * | 2025-09-19 | 2026-01-02 | 兰州名德药业有限公司 | 一种藏绵羊胚胎ⅲ型胶原蛋白和制备方法及其用途 |
| CN121338086B (zh) * | 2025-12-22 | 2026-04-17 | 浙江崇山生物制品有限公司 | 一种用于慢性创面修复的丝素/胶原蛋白复合海绵的制备方法 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990013320A1 (en) * | 1989-05-05 | 1990-11-15 | Ferrosan A/S | Haemostatic sponge |
| US5001169A (en) * | 1984-10-24 | 1991-03-19 | Collagen Corporation | Inductive collagen-based bone repair preparations |
| DE4404625C1 (de) * | 1994-02-14 | 1995-04-13 | Ludwig Dr Baumgartner | Verfahren zur Inaktivierung thermolabiler Viren in biologischem Material unter Beibehaltung der kollagenen Eigenschaften |
| WO2001037861A1 (en) * | 1999-11-22 | 2001-05-31 | Anamar Medical Ab | A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance |
| RU2193897C2 (ru) * | 1996-04-04 | 2002-12-10 | Бакстер Акциенгезельшафт | Гемостатическая губка, основанная на коллагене, способ ее получения, повязка для ран, включающая такую губку, и набор для приготовления повязки для ран |
| WO2004007707A1 (en) * | 2002-07-10 | 2004-01-22 | National Blood Authority | Process for producing a virus-inactivated thrombin preparation |
| CN101612113A (zh) * | 2009-06-23 | 2009-12-30 | 武汉海特生物制药股份有限公司 | 一种神经生长因子海绵剂及其制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4066083A (en) | 1976-06-03 | 1978-01-03 | Pentapharm A.G. | Sterile surgical collagen product |
| JPH01303152A (ja) * | 1988-06-01 | 1989-12-07 | Katakura Chitsukarin Kk | 止血材およびその製造法 |
| CA2107473A1 (en) * | 1991-04-08 | 1992-10-09 | Keiji Fujioka | Porous solid formulations containing proteinaceous physiologically active substances |
| US6180606B1 (en) | 1994-09-28 | 2001-01-30 | Gensci Orthobiologics, Inc. | Compositions with enhanced osteogenic potential, methods for making the same and uses thereof |
| US6686191B1 (en) * | 1995-09-22 | 2004-02-03 | Bayer Healthcare Llc | Preparation of virally inactivated intravenously injectable immune serum globulin |
| US5814328A (en) | 1997-01-13 | 1998-09-29 | Gunasekaran; Subramanian | Preparation of collagen using papain and a reducing agent |
| AU716137B2 (en) | 1997-01-16 | 2000-02-17 | Cohesion Corporation | Lyophilized collagen-based biomaterials, process of preparation and uses thereof |
| AT407117B (de) | 1997-09-19 | 2000-12-27 | Immuno Ag | Fibrinschwamm |
| CN1141981C (zh) | 1999-02-04 | 2004-03-17 | 李校坤 | 促进脊髓组织损伤愈合的海绵材料其制备方法及应用 |
| JP4334719B2 (ja) * | 1999-08-27 | 2009-09-30 | 学校法人 関西大学 | 凍結保護物質の調製方法 |
| PL206194B1 (pl) | 2001-01-25 | 2010-07-30 | Nycomed Pharma Asnycomed Pharma As | Sposób wytwarzania zawiesiny cząstek fibrynogenu i trombiny, zawiesina zawierająca fibrynogen, trombinę i alkohol oraz sposób powlekania nośnika taką zawiesiną |
| CN1183941C (zh) * | 2002-09-28 | 2005-01-12 | 陈武德 | 一种治疗心脑血管病的中药水丸 |
| CN1197631C (zh) | 2002-12-30 | 2005-04-20 | 中国皮革和制鞋工业研究院 | 一种含有表皮生长因子的皮肤组织工程支架的构建方法 |
| GB0303999D0 (en) | 2003-02-21 | 2003-03-26 | Devro Plc | Collagen film |
| CN100444901C (zh) * | 2003-08-07 | 2008-12-24 | 唐宝辉 | 生物膨胀性止血海绵及其生产工艺 |
| WO2005053617A2 (en) * | 2003-11-28 | 2005-06-16 | Alternative Sourced Collagen, Llc | Compositions and methods comprising collagen |
| CN101001649B (zh) * | 2004-07-09 | 2011-08-31 | 弗罗桑医疗设备公司 | 包括透明质酸的止血组合物及其制备方法 |
| CN100444902C (zh) | 2005-08-15 | 2008-12-24 | 上海其胜生物制剂有限公司 | 胶原蛋白海绵的制备工艺 |
| CN101505723A (zh) * | 2006-06-22 | 2009-08-12 | 南佛罗里达大学 | 胶原支架、具有其的医用植入物以及使用方法 |
| CA2663722C (en) | 2006-09-21 | 2014-12-09 | Purdue Research Foundation | Collagen preparation and method of isolation |
| US8088323B2 (en) | 2007-02-27 | 2012-01-03 | Ppg Industries Ohio, Inc. | Process of electrospinning organic-inorganic fibers |
| CN101279104B (zh) * | 2007-04-05 | 2011-05-11 | 王珊珊 | 一种含有生长因子的胶原蛋白海绵的制备方法 |
| DE102007037056A1 (de) * | 2007-07-24 | 2009-01-29 | Aesculap Ag | Hämostyptikum |
| CN101486748B (zh) | 2008-01-15 | 2011-11-02 | 浙江新和成股份有限公司 | 一种5，7-双烯胆固醇酯的制备方法 |
| JP5458237B2 (ja) * | 2008-04-02 | 2014-04-02 | ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 | アパタイト／コラーゲン複合体からなる膨張性多孔体、及びその製造方法 |
| WO2010062049A2 (ko) * | 2008-11-03 | 2010-06-03 | Lee Jae In | 형상기억합금을 이용한 동력발생장치 |
| CN102357259A (zh) | 2011-07-28 | 2012-02-22 | 王珊珊 | 一种生物蛋白海绵及其制备方法 |
-
2011
- 2011-07-28 CN CN2011102127130A patent/CN102357259A/zh active Pending
-
2012
- 2012-06-07 US US14/235,355 patent/US9439999B2/en active Active
- 2012-06-07 KR KR1020147004371A patent/KR20140034938A/ko not_active Ceased
- 2012-06-07 EP EP12817662.5A patent/EP2737910B1/en active Active
- 2012-06-07 KR KR1020167024422A patent/KR101717266B1/ko active Active
- 2012-06-07 RU RU2014103549/15A patent/RU2584348C2/ru active
- 2012-06-07 WO PCT/CN2012/076577 patent/WO2013013537A1/zh not_active Ceased
- 2012-06-07 JP JP2014521915A patent/JP5887407B2/ja active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5001169A (en) * | 1984-10-24 | 1991-03-19 | Collagen Corporation | Inductive collagen-based bone repair preparations |
| WO1990013320A1 (en) * | 1989-05-05 | 1990-11-15 | Ferrosan A/S | Haemostatic sponge |
| DE4404625C1 (de) * | 1994-02-14 | 1995-04-13 | Ludwig Dr Baumgartner | Verfahren zur Inaktivierung thermolabiler Viren in biologischem Material unter Beibehaltung der kollagenen Eigenschaften |
| RU2193897C2 (ru) * | 1996-04-04 | 2002-12-10 | Бакстер Акциенгезельшафт | Гемостатическая губка, основанная на коллагене, способ ее получения, повязка для ран, включающая такую губку, и набор для приготовления повязки для ран |
| WO2001037861A1 (en) * | 1999-11-22 | 2001-05-31 | Anamar Medical Ab | A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance |
| WO2004007707A1 (en) * | 2002-07-10 | 2004-01-22 | National Blood Authority | Process for producing a virus-inactivated thrombin preparation |
| CN101612113A (zh) * | 2009-06-23 | 2009-12-30 | 武汉海特生物制药股份有限公司 | 一种神经生长因子海绵剂及其制备方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018074951A1 (ru) * | 2016-10-21 | 2018-04-26 | Балабаньян, Вадим Юрьевич | Антибактериальная белковая губка для химиотерапии инфицированных ран и способ ее получения |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013013537A1 (zh) | 2013-01-31 |
| JP2014521415A (ja) | 2014-08-28 |
| KR101717266B1 (ko) | 2017-03-16 |
| KR20140034938A (ko) | 2014-03-20 |
| EP2737910A4 (en) | 2015-05-27 |
| KR20160108599A (ko) | 2016-09-19 |
| US9439999B2 (en) | 2016-09-13 |
| EP2737910B1 (en) | 2018-12-19 |
| CN102357259A (zh) | 2012-02-22 |
| JP5887407B2 (ja) | 2016-03-16 |
| EP2737910A1 (en) | 2014-06-04 |
| US20140235539A1 (en) | 2014-08-21 |
| RU2014103549A (ru) | 2015-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9439999B2 (en) | Composite collagen sponge and preparation method thereof | |
| JP6284987B2 (ja) | ウイルス不活化血小板抽出物、その使用及び調製 | |
| Loo et al. | Ultrashort peptide nanofibrous hydrogels for the acceleration of healing of burn wounds | |
| AU2021202201A1 (en) | Extracellular matrix compositions | |
| US20130245528A1 (en) | Compositions Comprising Placental Collagen for Use in Wound Healing | |
| US20240335479A1 (en) | Biological material impregnated with a solution comprising exosomes | |
| CN111393521A (zh) | 一种水母胶原蛋白的提取方法 | |
| CN106729984A (zh) | 一种鱼胶原蛋白修复海绵及其制备方法 | |
| CN112717200A (zh) | 一种重组人胶原蛋白可吸收水凝胶皮肤支架及其制备方法、使用方法 | |
| CN115491400B (zh) | 一种促进皮肤创伤修复的海洋生物肽及其制备方法和应用 | |
| JP2025531968A (ja) | 皮膚損傷外用薬の調製における絹フィブロイン融合タンパク質の使用 | |
| Wang et al. | Development of mADM-collagen wound dressings for mimicking native skin architecture to enhance skin wound healing | |
| WO2007139291A1 (en) | A pharmaceutical composition for treatment of wounds containing blood plasma component | |
| WO2013045689A1 (en) | Therapeutic use of gelatin hydrogels with a gel-sol transition at body temperature | |
| WO2013025940A1 (en) | Angiogenesis promoted by alpha-keratose | |
| CN115505618B (zh) | 一种促进皮肤创伤修复的海洋贝类活性肽 | |
| CN115040636A (zh) | 多肽在促进软骨再生或修复中的用途 | |
| CN118139646A (zh) | 一种鲵皮肤分泌物水解液及其制备方法和应用 | |
| RU2646804C1 (ru) | Офтальмологическое средство для регенерации роговицы глаза | |
| CN113194965B (zh) | 用于治疗伤口的药物组合物 | |
| Woo et al. | Preparation of UV-curable gelatin derivatives for drug immobilization on polyurethane foam: development of wound dressing foam | |
| KR101095940B1 (ko) | 주사가능한 불용성 글로빈 이식체 | |
| Wang et al. | Enhanced wound healing function of fibronectin variants via fusing with platelet factor 4 | |
| CN119345438B (zh) | 一种脱细胞外基质生物型敷料及其制备方法 | |
| CN120082617A (zh) | 提高胶原蛋白生物安全性的制备方法、产品及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20170207 |